LEUPROLIDE

Prostatic Neoplasms

Dana-Farber Cancer Instituteprotein_peptidePhase 4 / ApprovedActive

BB

71/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 70/ 100
Competitive Position: 73/ 100

Competitive context

73 Active assets in the Prostatic Neoplasms cohort.

Asset / Sponsor	Phase	Rating
Docetaxel Merck Sharp & Dohme LLC	Phase 4	BBB
Degarelix Novartis Pharmaceuticals	Phase 4	BBB
PREDNISONE TABLETS Merck Sharp & Dohme LLC	Phase 3	BBB
Abiraterone Acetate Qilu Pharmaceutical Co., Ltd.	Phase 3	BB
RADIUM RA-223 Bayer	Phase 3	BB

View all 50 →

Same molecule, other indications

LEUPROLIDE is also rated in:

prostate carcinomaDormant

BBB

Indicative ·

74 / 100

metastatic prostate carcinomaDormant

BBB

Indicative ·

72 / 100

prostate adenocarcinomaDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.